RxDoctor Payments Data

Elizabeth Whang, NP

Family · New York, NYNPI 1487352290

Payments from drug & device makers

$2,143in general payments, 2019–2025

Across 99 payments — averaging $21.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Urogen Pharma, Inc.$513
  • Endo USA, Inc.$428
  • Procept Biorobotics Corporation$304
  • ABC Home Medical Supply, Inc.$228
  • Hollister Incorporated$150
  • Endo Pharmaceuticals Inc.$116
  • plus $404 from 7 others

What the payments were for

  • Food & beverage$2,143100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Urogen Pharma, Inc.20$513
Endo USA, Inc.39$428
Procept Biorobotics Corporation2$304
ABC Home Medical Supply, Inc.6$228
Hollister Incorporated5$150
Endo Pharmaceuticals Inc.6$116
Dentsply IH AB6$114
Antares Pharma, Inc.5$100
AbbVie3$69
Astellas Pharma US Inc3$41
Sumitomo Pharma America, Inc.2$39
Civco Medical Instruments1$26
Novo Nordisk1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,143 in reported general payments places this provider in the 85th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$108,391
Medicare patients
491
Services billed
17,916

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron232$184,735
MyrbetriqMirabegron141$100,240
XyostedTestosterone Enanthate26$29,009
Silodosin163$12,840
Mirabegron ErMirabegron16$11,489
Tadalafil53$5,849
Fosfomycin Tromethamine16$4,372
Finasteride209$3,068
Methenamine Hippurate62$2,987
Tamsulosin Hcl193$2,569
Fesoterodine Fumarate ErFesoterodine Fumarate14$2,341
Alfuzosin Hcl ErAlfuzosin Hcl87$2,136
Solifenacin Succinate72$2,108
Trospium Chloride54$2,024
Cefpodoxime Proxetil80$1,738

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$39$184,735232 claims
Astellas Pharma US IncMyrbetriq$41$100,240141 claims
Antares Pharma, Inc.Xyosted$100$29,00926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,883 family providers in New York.

Other family in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →